SCHEMBL4995098

SCHEMBL4995098

COc1nnc(-c2ccccn2)c2cc(C(=O)O)ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.48
KDM6B O15054 2/20 0.48
KDM5C P41229 2/20 0.48
KDM4C Q9H3R0 2/20 0.48
KDM2A Q9Y2K7 2/20 0.48
KDM3A Q9Y4C1 2/20 0.48
KDM4A O75164 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
GABRA5 P31644 1/20 0.40
SMO Q99835 2/20 0.39
ADORA3 P0DMS8 2/20 0.39
METAP1 P53582 1/20 0.39
MAPT P10636 3/20 0.38
PARP1 P09874 1/20 0.38
SQOR Q9Y6N5 1/20 0.38
ABL1 P00519 1/20 0.38
BCR P11274 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4995199 0.83 L3MBTL1 (0.55) KDM4EL3MBTL1ALDH1A1CYP1A2CYP2C19
SCHEMBL4990697 0.82 KDM4E (0.52) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL4993747 0.80 CA1 (0.50) KDM4EL3MBTL1ALDH1A1CYP1A2CYP2C19
SCHEMBL2459889 0.77 MAPT (0.53) KDM4EMAPT
SCHEMBL4993719 0.74 HTT (0.46) KDM4EL3MBTL1ALDH1A1CYP1A2CYP2C19
SCHEMBL4984409 0.73 CA1 (0.44) KDM4EL3MBTL1ALDH1A1CYP1A2CYP2C19
SCHEMBL4994369 0.73 CA1 (0.44) KDM4EL3MBTL1ALDH1A1CYP1A2CYP2C19
SCHEMBL4993736 0.72 HTT (0.46) KDM4EL3MBTL1ALDH1A1CYP1A2CYP2C19
SCHEMBL5256098 0.71 KDM4C (0.55) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL13117741 0.71 KDM4C (0.60) KDM4EKDM6BKDM5CKDM4CKDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349836-B2 Phthalazine derivatives as inhibitors of protein kinase ARALDI GIAN-LUCA (US) 2013-01-08 US disclosed
EP-2131656-A2 PHTHALAZINE DERIVATIVES Forest Laboratories Holdings Limited (BM) 2009-12-16 EP disclosed
US-20080146547-A1 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-19 US disclosed
WO-2008061108-A2 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146547-A1 PHTHALAZINE DERIVATIVES CDK5, HIPK2, PACSIN2 KDM4E 761/4885KDM6B 1112/4885KDM5C 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.